Neogen Corporation has renewed its partnership with the United States Equestrian Federation, extending a collaboration that began in April 2024. Through this ongoing alliance, Neogen will continue to provide educational resources and support to US Equestrian members, focusing on prevention and treatment protocols for equine botulism-a serious neuromuscular condition in horses. As an industry leader in equine health, Neogen manufactures BotVax® B, the only USDA-approved vaccine for botulism Type B in horses. Both organizations emphasize the importance of education and prevention in safeguarding the health and well-being of equine athletes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neogen Corporation published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.